IDH1 R132H - Format: 500 µl

QM002, Ms, 0.5 ml Conc.

Technische Daten
Reaktivität AK:Human, others not tested.
Format AK:Concentrate
Ig Unterklasse:IgG1
Immunogen:Synthetic peptide of human IDH1/Isocitrate dehydrogenase
Anwendung AK:IHC(p),IHC(f)
Fixierung:1) NOTOXhisto 2) Formalin
Zelluläre Lokalisation:Cytoplasmic, peroxisome
Kontrolle:Oligodendroglioma, diffuse astrocytoma
Lagerung AK:Store at 2 - 8 °C. Do not use after expiration date indicated on the vial.
Synonyme:Cytosolic NADP isocitrate dehydrogenase, Cytosolic NADP-isocitrate dehydrogenase, ICDH, IDCD, IDH, IDHC, Idh1, IDHC_HUMAN, IDP, IDPC, Isocitrate dehydrogenase [NADP] cytoplasmic, Isocitrate dehydrogenase 1 (NADP+) soluble, NADP dependent isocitrate dehydrogenase cytosolic, NADP dependent isocitrate dehydrogenase peroxisomal, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase, PICD.
Verfügbar in folgenden Ländern:world wide
Status:RUO - IVD validation in progress

Isocitrate dehydrogenase 1 is a cytoplasmic enzyme that catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming alpha-ketoglutarate and CO2 in a two step reaction. It is expressed in a wide range of species and also in organisms that lack a complete citric acid cycle. The IDH1 R132H point mutation is shown in more than 70 % of gliomas. The antibody QM002 is highly specific in detection of the mutant protein and contributes the differentiation between a glioblastoma and an anaplastic glioma.


[1] Yan H, Parson W, Jin G et al. (2009). N Engl J Med. 360:765-773.
[2] Capper D, Wei§ert S, Balss J et al. (2009). Acta Neuropathol. 118:599-601.
[3] Mardis ER, Ding L, Dooling DJ et al. (2009). N Engl J Med. 361:1058-1066.
[4] Camelo-Piragua S, Jansen M, Ganguly et al. (2010). Acta Neuropathol. 119:509-511.
[5] Horbinsky C, Kofler J, Yeaney G et al. (2011). Brain Pathol. 21(5):564-74.